Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Relevance of pharmacokinetics in narrow therapeutic index drugs.

Benet LZ.

Transplant Proc. 1999 May;31(3):1642-4; discussion 1675-84. No abstract available.

PMID:
10331032
2.

Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve.

Belitsky P, Mahalati K, West K, Sketris I.

Transplant Proc. 1999 May;31(3):1667-8. No abstract available.

PMID:
10331038
3.

Issues in cyclosporine drug substitution: implications for patient management.

Bartucci MR.

J Transpl Coord. 1999 Sep;9(3):137-42; quiz 143-4. Review.

PMID:
10703396
4.

Scientific and professional concerns regarding product interchange and subsequent monitoring of cyclosporine and other critical dose drugs.

Barr WH.

Transplant Proc. 1999 May;31(3):1645-8; discussion 1675-84. Review. No abstract available.

PMID:
10331033
5.

Recommendations concerning the introduction of generic formulations of cyclosporine.

Kahan BD.

Transplant Proc. 1999 May;31(3):1634; discussion 1675-84. No abstract available.

PMID:
10331030
6.

Considerations concerning generic formulations of immunosuppressive drugs.

Kahan BD.

Transplant Proc. 1999 May;31(3):1635-41. No abstract available.

PMID:
10331031
7.

Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine.

Johnston A, Keown PA, Holt DW.

Ther Drug Monit. 1997 Aug;19(4):375-81.

PMID:
9263375
8.

Relationship of pharmacokinetics to clinical outcomes.

Levy GA.

Transplant Proc. 1999 May;31(3):1654-8. Review. No abstract available.

PMID:
10331035
9.

Bioequivalence criteria for cyclosporine.

Johnston A, Holt DW.

Transplant Proc. 1999 May;31(3):1649-53. Review. No abstract available.

PMID:
10331034
10.

Therapeutic drug monitoring of cyclosporine.

Jorga A, Holt DW, Johnston A.

Transplant Proc. 2004 Mar;36(2 Suppl):396S-403S. Review.

PMID:
15041374
11.

Lessons from the Neoral Global Database for renal transplantation.

Helderman JH.

Transplant Proc. 1999 May;31(3):1659-63. No abstract available.

PMID:
10331036
12.

The impact of cyclosporin formulation on clinical outcomes.

Holt DW, Johnston A.

Transplant Proc. 2000 Nov;32(7):1552-5. Review. No abstract available.

PMID:
11119831
13.

Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients.

Cattaneo D, Merlini S, Baldelli S, Bartolini B, Nicastri A, Gotti E, Remuzzi G, Perico N.

Ther Drug Monit. 2006 Oct;28(5):643-9.

PMID:
17038879
14.

Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation.

Holt DW.

Curr Opin Nephrol Hypertens. 2002 Nov;11(6):657-63. Review.

PMID:
12394613
15.

A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001.

Pollard S, Nashan B, Johnston A, Hoyer P, Belitsky P, Keown P, Helderman H; CONSENT: Consensus on Substitution in European Transplantation.

Clin Ther. 2003 Jun;25(6):1654-69. Review.

PMID:
12860490
16.

Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.

Loichot C, Bentue-Ferrer D, Bernard N, Bonardet A, Boulieu R, Kergueris MF, Paintaud G, Peytavin G, Simon N, Marquet P; Therapeutic Drug Monitoring Group of the French Pharmacological Society.

Fundam Clin Pharmacol. 2006 Feb;20(1):91-6.

PMID:
16448399
17.

Do we have the same clinical results with Neoral and Equoral treatment in kidney transplant recipients? A pilot study.

Spasovski G, Masin-Spasovska J, Ivanovski N.

Transpl Int. 2008 Apr;21(4):392-4. Epub 2007 Dec 5. No abstract available.

18.
19.

Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy.

Barbari A, Stephan A, Masri M, Mourad N, Kamel G, Kilani H, Karam A, Daya IA.

Transplant Proc. 2003 Nov;35(7):2742-4. No abstract available.

PMID:
14612101
20.

Bioavailability versus bioequivalence: the cyclosporine model.

Masri MA.

Exp Clin Transplant. 2003 Dec;1(2):119-24.

Supplemental Content

Support Center